查看文章

The purpose of this study was to evaluate differences between patients receiving ¹⁸F-fluciclovine and ⁶⁸Ga-prostate-specific membrane antigen (⁶⁸Ga-PSMA-11) for biochemically recurrent prostate cancer at a tertiary medical center. All ¹⁸F-fluciclovine and ⁶⁸Ga-PSMA-11 PET studies performed at the University of California San Francisco from October 2015 to January 2020 were reviewed. Age, race/ethnicity, primary language, body mass index, insurance type, and home address were obtained through the electronic medical record. A logistic regression model was used to evaluate the predictor variables. In total, 1,502 patients received ⁶⁸Ga-PSMA-11 and 254 patients received ¹⁸F-fluciclovine. Black patients had increased odds of receiving imaging with ¹⁸F-fluciclovine versus ⁶⁸Ga-PSMA-11 compared with non-Hispanic White patients (odds ratio, 3.88; 95% CI, 1.90–7.91). There were no …